Out-license Agreements - Additional Information (Detail) - USD ($)		1 Months Ended		3 Months Ended				6 Months Ended
	Oct. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Aug. 02, 2022	Dec. 31, 2021
License Collaboration And Manufacturing Agreements [Line Items]
License and collaboration revenue				$ 51,579,000		$ 3,870,000		$ 58,893,000	$ 7,422,000
Deferred revenue - long-term				43,329,000				43,329,000			$ 55,708,000
Bayer Research, Development, and License Agreement
License Collaboration And Manufacturing Agreements [Line Items]
Upfront cash payment received			$ 45,000,000.0
Additional upfront reimbursement payment for research and process development			15,000,000.0
Determined upfront payment for license in order to evaluate transaction price			45,000,000.0
Determined research and process development activities in order to evaluate transaction price			15,000,000.0
Determined additional specified translational activities in order to evaluate transaction price			$ 5,000,000.0
Bayer Technology Transfer Agreement
License Collaboration And Manufacturing Agreements [Line Items]
License agreement amount invoiced percentage					40.00%	20.00%
License agreement invoiced amount					$ 6,100,000	$ 3,100,000
License agreement total fee							$ 15,300,000
Bayer Manufacturing Agreement
License Collaboration And Manufacturing Agreements [Line Items]
Written acceptance of binding purchase order percentage		50.00%					50.00%
Bayer license agreement percentage of estimated supply price to be invoiced upon delivery		50.00%
Total estimated supply price		$ 13,100,000
Amount invoiced in March 2021 for 50% of total estimated supply price		$ 6,600,000
Determined fee constituted entire consideration included in transaction price								13,100,000
License and collaboration revenue				50,900,000		$ 3,900,000		57,600,000	$ 7,400,000
Deferred revenue											$ 51,500,000
Bayer Manufacturing Agreement | Subsequent Event [Member]
License Collaboration And Manufacturing Agreements [Line Items]
Agreement early termination liability										$ 4,200,000
Pierre Fabre Commercialization Agreement
License Collaboration And Manufacturing Agreements [Line Items]
Upfront cash payment received	$ 45,000,000.0							45,000,000.0
Royalty eligible to receive term after first commercial sale	12 years
Development or sales-based milestone payments earned or received								$ 0
Years of manufacturing and supplying cost								7 years
Determined upfront payment constituted entire consideration included in transaction price								$ 45,000,000
Pierre Fabre Commercialization Agreement | Long Term Liabilities
License Collaboration And Manufacturing Agreements [Line Items]
Deferred revenue - long-term				43,300,000				43,300,000
Pierre Fabre Commercialization Agreement | Current liabilities
License Collaboration And Manufacturing Agreements [Line Items]
Deferred revenue - long-term				$ 1,700,000				$ 1,700,000
Pierre Fabre Commercialization Agreement | Maximum
License Collaboration And Manufacturing Agreements [Line Items]
Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones	$ 318,000,000.0